title: (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis.
abstract: OBJECTIVE
  To evaluate the value of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in monitoring disease activity and predicting treatment response in idiopathic retroperitoneal fibrosis (iRPF).
  
  
  METHODS
  This prospective study was approved by the institutional review board. Informed consent was obtained from all patients. Twenty-six patients with iRPF receiving tamoxifen monotherapy underwent repeated FDG-PET (baseline and, if positive, at 3 months) and computed tomographic (CT) scanning (baseline, 4 and 8 months). Maximal RPF mass thickness in 3 different view directions was measured on each CT scan; FDG-uptake was semi-quantified using a visual 4-point scale. Initial and follow-up PET scan results were correlated with clinical, laboratory and CT scan follow-up data. Treatment outcome was the aggregate measure of clinical, laboratory and CT-documented response to tamoxifen.
  
  
  RESULTS
  FDG-PET was positive in 20 patients. Patients with positive PET scan result had higher C-reactive protein level (P=0.02) and larger mass size (P=0.01) compared with patients with negative PET scan result. Visual PET score correlated with C-reactive protein level (P=0.002) and CT-documented mass thickness (P=0.04). Visual PET score decreased following treatment (P<0.01). This decrease correlated with decrease in ESR (P<0.001) but not with CT-documented mass regression. Positive predicting value (PPV) of initial positive PET scan result was 0.63; PPV of negative follow-up PET scan result in patients with initial positive PET scan result was 0.66.
  
  
  CONCLUSIONS
  FDG-PET is valuable in detecting (recurrent) disease activity. Short-term follow-up with FDG-PET cannot be routinely recommended for the therapeutic evaluation of RPF disease in tamoxifen-treated patients.
authors.affiliation: Department of Radiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
authors.forename: I
authors.initials: I
authors.lastname: Jansen
authors.forename: T R
authors.initials: TR
authors.lastname: Hendriksz
authors.forename: S H
authors.initials: SH
authors.lastname: Han
authors.forename: A W L C
authors.initials: AW
authors.lastname: Huiskes
authors.forename: E F H
authors.initials: EF
authors.lastname: van Bommel
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D018450:Disease Progression; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012008:Recurrence; D012044:Regression Analysis; D012185:Retroperitoneal Fibrosis / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D013629:Tamoxifen / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D000209:Acute-Phase Proteins; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D019788:Fluorodeoxyglucose F18